Replies to post #171969 on Biotech Values

[DewDiligence]

PPHM—Yes, DD I agree. Pretty silly post.

It was more clueless than silly insofar as the poster clearly has no idea how clinical trials are conducted.

About as silly as some of the tweets coming from [Adam Feuerstein], [Patrick Crutcher], and others. Does AF really think they are still looking for the money to run the trial? Pretty naive statement.

Please explain why Feuerstein’s statement about funding is naïve. Didn’t PPHM just file a $100M shelf registration?

And PC’s comment about the cancer patients thinking twice about enrolling. So they should think twice about choosing a drug that could possibly double their survival and at worst is the current SOC.

I agree with Patrick; if I had NSCLC, I would certainly look elsewhere before settling for a placebo-controlled trial of Bavituximab. I would probably seek out a trial of one of the PD-1/PD-L1 agents.

Prediction: Enrolling 600 patients in the SUNRISE trial will take PPHM until at least 2016—if it can be done at all. Bookmark this post.